Moderna's defining moves.
The defining strategic moves at Moderna — each one explained and grounded in the record.
The Crossroads · Decision Forks
Moderna Didn't Get Lucky With COVID. It Got a Decade of Runway. Now the Clock Is Running Out.
Moderna's revenue collapsed 83% from its peak, and its $25 million RSV launch barely moved. The whole company now rests on a cancer-vaccine Phase 3 that hasn't reported and combo shots years from revenue. The next 24 months are binary, not managed.
8 min
The All-In Bet · Decision Forks
Moderna Bet Everything on a Platform It Never Got to Test. A Pandemic Tested It Instead.
By its 2018 IPO Moderna had raised $1.8B, shipped zero products, and was the biggest venture-backed biotech IPO ever. The bet wasn't on a drug. It was on a factory for drugs - and a virus, not the pipeline, became its first proof.
8 min
The Fall · Decision Forks
Moderna Earned a Decade's Revenue in Two Years. Then It Had to Build a Second Act From Scratch.
Moderna's COVID windfall hit $19.3 billion in 2022. By 2025 revenue was down to about $1.9 billion with a $2.8 billion net loss - and the diversification bet meant to rescue it sold only $25 million in its launch year.
8 min
The Moat Anatomy · Competitive Moats
Moderna's Patent Fortress Has No Walls. What It Has Is Harder to Copy.
The story is that Moderna owns mRNA. The record says otherwise: it paid $2.25 billion to settle the lipid patents it was already using, is fighting NIH over who invented the vaccine, and saw its Pfizer suit paused. The real moat is the thing no court can touch.
8 min
The Moat Anatomy · Moat Anatomy
Moderna Has a Platform and a Boom. Only One of Them Is Still Generating Revenue.
Moderna's pitch was never one vaccine - it was a programmable platform that could build any vaccine. But after the boom, the platform has shipped exactly one new product: mRESVIA, at $25M in 2024. The moat is real. It just hasn't started paying yet.
8 min